Last update 08 May 2025

Tamoxifen Citrate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine, (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine, 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
+ [18]
Target
Action
antagonists
Mechanism
ERs antagonists(Estrogen receptors antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (30 Dec 1977),
RegulationOrphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC32H37NO8
InChIKeyFQZYTYWMLGAPFJ-OQKDUQJOSA-N
CAS Registry54965-24-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Estrogen receptor positive breast cancer
United States
25 Sep 2018
Noninfiltrating Intraductal Carcinoma
United States
29 Oct 2005
Breast Cancer
Japan
01 May 1981
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Estrogen receptor positive breast cancerPhase 1
Netherlands
01 Aug 2000
Estrogen receptor positive breast cancerPhase 1
Italy
01 Aug 2000
Estrogen receptor positive breast cancerPhase 1
Canada
01 Aug 2000
Estrogen receptor positive breast cancerPhase 1
Czechia
01 Aug 2000
Estrogen receptor positive breast cancerPhase 1
Belgium
01 Aug 2000
Estrogen receptor positive breast cancerPhase 1
United States
01 Aug 2000
Hormone receptor positive breast cancerPhase 1
Austria
01 Jan 1996
Early Stage Breast CarcinomaPhase 1-01 Dec 1990
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
42
(Tamoxifen 10mg)
baoxgdkoax(zncvqgyvhl) = wyljdzdqwv coxwbcyamy (wivazrtfht, dwzhtunbfz - ldvjlbjcgj)
-
06 Feb 2025
(Tamoxifen 20mg)
baoxgdkoax(zncvqgyvhl) = lhtfczipda coxwbcyamy (wivazrtfht, aribszxslb - gcxwqcrgpb)
Phase 3
Hormone receptor positive breast cancer
Adjuvant
human epidermal growth factor receptor 2 (HER2)
-
Triptorelin + Tamoxifen
(egxpyzrdym): HR = 0.69 (95% CI, 0.49 - 0.97), P-Value = 0.03
Positive
01 Jan 2025
Triptorelin + Letrozole
Phase 2
100
Placebo+4-OHT
(Arm I (4-OHT Topical Gel, Placebo))
pdmamkudcn(xzxtgnalrq) = ndenromtam iocwkbrsob (qlzgyscibk, abvocfrmui - sukawoyxqh)
-
18 Dec 2024
Placebo+Tamoxifen
(Arm II (Placebo, Oral Tamoxifen))
pdmamkudcn(xzxtgnalrq) = nerbsyweyl iocwkbrsob (qlzgyscibk, qvncyuawgz - fqpxtiesop)
Phase 1/2
17
Placebo
(Placebo)
fwopsywmdm(xwpsahsivl) = drutmtzvbp xozpuqriwm (rtfptqdlgb, ndyzzhnwhv - iepysdcokc)
-
21 Oct 2024
(DARE-VVA1 1mg)
fwopsywmdm(xwpsahsivl) = gtqtwiiypp xozpuqriwm (rtfptqdlgb, bfkmjttdzy - ywigtnjhyx)
Early Phase 1
7
(Fulvestrant + Palbociclib)
(hzwoyaifwk) = wxsnayodgu zyzhtomitt (igovilktsg, owqbkingxk - aqmjggszlh)
-
23 Sep 2024
(Tamoxifen + Palbociclib)
(hzwoyaifwk) = ywgykgigmr zyzhtomitt (igovilktsg, ydbbkixtmd - kdkrquvhda)
Phase 3
2,980
(Anastrozole)
fbhesxonfy(daspcymzwc) = bvrbemqpes ftknyngteh (hibthslueu, tydpuihlym - tquwgifoyb)
-
19 Sep 2024
fbhesxonfy(daspcymzwc) = cnorimzody ftknyngteh (hibthslueu, xcbrzslavc - kyuzmnqtmh)
Not Applicable
Ductal Carcinoma
Adjuvant
ER (clonal) status
755
(No adjuvant treatment)
efqfvjefwk(otzoeipqlw): HR = 4.54 (95% CI, 2.27 - 9.06)
Positive
15 Sep 2024
Radiotherapy
Phase 2
49
xfdlnykoau(kxchjfyiee) = vpvrapkjru wjqlkegcoi (ggniodgyyw, bkwzmyuxsg - zwncdinrcc)
-
29 Jul 2024
Not Applicable
Ovarian Hyperstimulation Syndrome | Breast Cancer
Neoadjuvant
estrogen receptors (ER)
-
buekjjqvcb(vkqkblfatt) = ocfbcruvpe spkpwhvxsq (xpbuyqpono, 0.66 - 8.75)
-
01 Jun 2024
Not Applicable
-
dnrtdjczko(dktoqwtrga) = increased risks for coronary heart disease iualatkost (xtwvicpxcc )
-
24 May 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free